公开(公告)号：WO2006045347A1

公开(公告)日：2006-05-04

申请号：PCT/EP2005/001846

申请日：2005-02-22

Applicant: MEDINOVA AG ,  GRAF, Federico ,  GROB, Phillipp ,  BRASSART, Dominique

Inventor： GRAF, Federico ,  GROB, Phillipp ,  BRASSART, Dominique

IPC: A61K35/74

CPC classification number: A61K35/747 ,  A23L2/382 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/02 ,  A61K9/48 ,  A61K2035/115 ,  C12R1/225 ,  C12R1/23 ,  Y02A50/473 ,  A61K2300/00 ,  A23V2200/32 ,  A23V2200/3204

Abstract: The L. helveticus strain LH KS 300 (CNCM I-3360) is used for its ability to adhere to cervix HeLa and/or Caco-2 epithelial cells, its ability to inhibit urogenital and/or gastrointestinal pathogens adhesion and growth on said epithelial cells, its ability to kill urogenital and/or gastrointestinal pathogens and its ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within said epithelial cells and also further selected for its ability to modulate the immune response of modulate the immuno competent cells, e.g. at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome. Pharmaceutical preparations containing said lactic acid bacteria strain useful for establishing, maintaining or restoring a balanced and healthy urogenital flora in females throughout life and corresponding methods of therapeutic or prophylactic treatment using them.

Abstract translation: 使用瑞士螺杆菌LH KS 300（CNCM I-3360）具有粘附到子宫颈HeLa和/或Caco-2上皮细胞的能力，其在所述上皮细胞上抑制泌尿生殖和/或胃肠道病原体粘附和生长的能力 ，其杀死泌尿生殖和/或胃肠道病原体的能力及其抑制所述上皮细胞内泌尿生殖和/或胃肠道病原体内源化的能力，还进一步选择调节免疫感受态细胞的免疫应答的能力，例如 在阴道和/或胃肠道水平，特别是抑制炎性综合征以及感染性综合征。 含有所述乳酸菌菌株的药物制剂，其用于建立，维持或恢复整个生命中女性的平衡和健康的泌尿生殖菌群，以及使用它们的相应治疗或预防治疗方法。